Vector VestAdvertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

TTNP RSS Feed
Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rentier, TRUTH, matthewverymuch
Search This Board:
Last Post: 1/28/2015 9:41:15 AM - Followers: 165 - Board type: Free - Posts Today: 1


 






Products


Probuphine®-This study is enrolling participants by invitation only.

Click For Link To ClinicalTrials.gov


*November 20, 2014 -  the study is 100% enrolled.
                                                                    * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For cnn.com Link 


Sponsor:

Braeburn Pharmaceuticals


ClinicalTrials.gov Identifier:
Information provided by (Responsible Party):
NCT02180659
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals









Probuphine Graphic

 

 

 

Continuous Drug Delivery Technology

 

The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.

 



Fanapt® (iloperidone)

 

Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.




Company Overview



Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.

 

Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


 

The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] www.otcbb.com) quotations system. For further information please contact info@titanpharm.com

 

Management Team

President
Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.

 



Board of Directors

 
 
  






 

Strategic Alliances


In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.

 





Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products

In addition to the potential royalty revenues from iloperidone, Titan is currently focused on adding value to the company from these assets, particularly Probuphine. Additional information on Probuphine and other programs are available in the next sections. If you are interested in learning more, please contact Sunil Bhonsle, President, at     sbhonsle@titanpharm.com

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TTNP
Current Price
Volume:
Bid Ask Day's Range
Wiki
TTNP News: Current Report Filing (8-k) 12/04/2014 12:24:57 PM
TTNP News: Quarterly Report (10-q) 11/13/2014 04:43:30 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:13:05 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 12:08:51 PM
TTNP News: Statement of Ownership (sc 13g) 10/10/2014 10:20:57 AM
PostSubject
#3684  Sticky Note ****Addicts DESPERATELY Waiting For A Lifesaver**** TRUTH 09/27/14 11:41:37 AM
#4181   Guess i over estimated the clout of sheff...appears matthewverymuch 01/28/15 09:41:14 AM
#4179   Your concern is well founded too. The Rentier 01/27/15 05:50:04 PM
#4178   Seems some of us do, some don't... Rentier 01/27/15 05:43:54 PM
#4177   Zacks investment research has a buy also. To PsD 01/27/15 11:32:26 AM
#4176   My opinions are jaundiced by the Iloperidone episode TRUTH 01/27/15 08:41:19 AM
#4174   Well said TRUTH bluejacket6 01/27/15 08:22:33 AM
#4173   I think Titan should fair better this time shadolane 01/27/15 07:59:09 AM
#4172   the first trails were done with FDA agreement TRUTH 01/27/15 07:25:15 AM
#4171   I agree with all of your comments. shadolane 01/27/15 06:29:41 AM
#4170   True even the FDA's own board review was TRUTH 01/26/15 10:01:14 PM
#4169   .80....owned for 2 years. Patience, indeed. matthewverymuch 01/26/15 09:49:27 PM
#4168  Restored Roth Capitol rates TTNP a buy! basssque 01/26/15 09:37:47 PM
#4158   Spheramine days...ahh yes Bob Stocks 01/26/15 08:41:11 PM
#4153   I do fallow ,but not so close that sanders11 01/26/15 08:28:10 PM
#4149   Exactly, what does your previous post have to Rentier 01/26/15 08:10:59 PM
#4147   Rentier what is your point? Anyway i bought sanders11 01/26/15 08:03:41 PM
#4142  Restored No chit...we all know the story... Bob Stocks 01/26/15 07:55:52 PM
#4141   True even the FDA's own board review was Rentier 01/26/15 07:54:24 PM
#4140   All the data from them has been positive Bob Stocks 01/26/15 07:53:39 PM
#4138   Well i was in TTNP when it was sanders11 01/26/15 07:51:30 PM
#4137   Why are the up coming phase 3 results Rentier 01/26/15 07:49:17 PM
#4136   I don't know...higher from here that's all i know Bob Stocks 01/26/15 07:39:54 PM
#4135   What is the potential share price here after sanders11 01/26/15 07:37:30 PM
#4134   Well, i don't have a crystal ball...but Phase Bob Stocks 01/26/15 07:27:39 PM
#4133   How much higher and when? Since the Rentier 01/26/15 07:25:01 PM
#4132  Restored Roth Capital's 4 Reasons To Be Bullish On sanders11 01/26/15 07:20:59 PM
#4131   chart short term and long term is wound spottrader 01/26/15 06:39:33 PM
#4130   Patience guys...this will be much higher Bob Stocks 01/26/15 05:14:58 PM
#4129   3.2 million shares, and up 1.4 cents. Clearly matthewverymuch 01/26/15 04:29:43 PM
#4128   Guess SA is late to the game with bluejacket6 01/26/15 04:06:45 PM
#4127   Scroll down to see truth's post matthewverymuch 01/26/15 02:36:05 PM
#4126   SA's Sarah Roden bluejacket6 01/26/15 02:32:35 PM
#4125   Research is there, late innings in this ballgame, bluejacket6 01/26/15 01:47:40 PM
#4124   Exactly. Moves based on fundamentals. That is what matthewverymuch 01/26/15 01:21:07 PM
#4123   I'm not interested in pump and dump either. shadolane 01/26/15 01:18:58 PM
#4122   Could there be a ton of short selling matthewverymuch 01/26/15 01:09:25 PM
#4121   It's hard to believe that such huge daily shadolane 01/26/15 12:57:27 PM
#4120   They started collecting data already on the recruits TRUTH 01/26/15 11:59:52 AM
#4119   Yes very much so his last 5 plays dave86 01/26/15 11:51:06 AM
#4118   So, you are a sheff acolyte? matthewverymuch 01/26/15 11:50:03 AM
#4117   Bought some just now at .51 really like dave86 01/26/15 10:46:21 AM
#4116   Thanks, truth. Don't know how to get the matthewverymuch 01/26/15 10:21:01 AM
#4115   Roth Capital’s 4 Reasons to be Bullish on TRUTH 01/26/15 10:18:23 AM
#4113   i took a gamble bought at ask today.. blindman28 01/26/15 09:58:13 AM
#4112   They started collecting data already on the recruits turks 01/25/15 12:56:33 PM
#4111  Restored .30's coming soon maxxm 01/25/15 03:22:54 AM
#4110   This is going to run next week. The Lt_investor 01/25/15 02:08:31 AM
#4109   lol this is a great gamble from under AntiMarketMaker 01/24/15 04:31:26 PM
#4108   They load up months before a promo and AntiMarketMaker 01/23/15 09:10:04 PM
#4107   What do you mean by front loaders? matthewverymuch 01/23/15 08:14:59 PM
PostSubject